Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055321 | 0.78 | GAA (0.37) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2383188 | 0.75 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| Ethylene Glycol SCHEMBL15272693 | 0.73 | KMT2A (0.38) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8394723 | 0.71 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8796333 | 0.71 | ALDH1A1 (0.34) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL26613616 | 0.71 | ALDH1A1 (0.39) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL28611540 | 0.71 | KMT2A (0.39) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL777187 | 0.70 | GAA (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL29367126 | 0.70 | GAA (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL76249 | 0.70 | GAA (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759515-B2 | Process for the preparation of tenofovir disoproxil fumarate | MYLAN LABORATORIES LIMITED (IN) | 2014-06-24 | — | — | US | claimed |
| EP-2545063-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | Matrix Laboratories Ltd (IN) | 2013-01-16 | — | — | EP | claimed |
| US-20130005969-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MYLAN LABORATORIES LIMITED (IN) | 2013-01-03 | — | — | US | claimed |
| WO-2011111074-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MATRIX LABORATORIES LTD (IN) | 2011-09-15 | — | — | WO | claimed |
| EP-2362731-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8759515-B2 | Process for the preparation of tenofovir disoproxil fumarate | MYLAN LABORATORIES LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-8759515-B2 | Process for the preparation of tenofovir disoproxil fumarate | MYLAN LABORATORIES LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| EP-2545063-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | Matrix Laboratories Ltd (IN) | 2013-01-16 | — | — | EP | disclosed |
| EP-2545063-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | Matrix Laboratories Ltd (IN) | 2013-01-16 | — | — | EP | disclosed |
| US-20130005969-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MYLAN LABORATORIES LIMITED (IN) | 2013-01-03 | — | — | US | disclosed |
| US-20130005969-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MYLAN LABORATORIES LIMITED (IN) | 2013-01-03 | — | — | US | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2011111074-A3 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MATRIX LABORATORIES LTD (IN) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011111074-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MATRIX LABORATORIES LTD (IN) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011111074-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | MATRIX LABORATORIES LTD (IN) | 2011-09-15 | — | — | WO | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2362731-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010051206-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-1742642-B1 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | ALDH1A1 1887/4885CYP3A4 2052/4885CYP2C9 3321/4885 |
| US-20130005969-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE | TYMP, PNP, MTAP | ALDH1A1 3768/4885CYP3A4 139/4885CYP2C9 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.